ArticleSpinal cord2026
Passive immunotherapy targeting pathogenic tau restores neuronal structure and function following spinal cord injury.
Article in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designAnimal study.
objectivesTo determine whether eliminating cis pT231-tau with a specific monoclonal antibody can restore neuronal structure and function after spinal cord injury (SCI).
settingRoyan Institute, Tehran, Iran.
methodsAdult Wistar rats underwent SCI induction using the NYU impactor device. Animals received treatment with cis pT231-tau monoclonal antibody or placebo. Outcomes were assessed via immunostaining, immunoblotting, and the Basso, Beattie, and Bresnahan (BBB) behavioral test to evaluate motor function recovery.
resultsTreatment with cis pT231-tau monoclonal antibody reduced inflammatory markers, enhanced myelin sheath formation, increased NF200 protein expression, and decreased GFAP levels compared with placebo. Behavioral testing indicated improved motor function in treated animals.
conclusionsEliminating cis pT231-tau using a specific monoclonal antibody mitigates neuronal damage and promotes structural and functional recovery following SCI, highlighting its therapeutic potential.
Indexed as
Identifiers
41917204What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.